LRP4 and myasthenia gravis: Currently, the NIMBLE trial (Phase III randomized, placebo-controlled trial) is evaluating pozelimab + cemdisiran in both AChR and LRP4 myasthenia gravis patients, with the primary outcome being the MG-ADL score at 24 weeks.